Who we are

Apexus works with more than 29,000 health care providers across the United States to lower their costs for purchasing outpatient pharmaceutical products, allowing them to stretch their resources to serve more low-income and uninsured patients. As the exclusive contractor for the 340B Drug Pricing Program, managed by the Health Resources and Service Administration (HRSA), Apexus negotiates significant discounts for branded and generic pharmaceuticals while working with providers to help them comply with 340B regulations and guidance. Apexus works closely with HRSA's Office of Pharmacy Affairs to improve the integrity of the 340B program. Enroll today!

How Apexus Can Help You:



Negotiating with hundreds of pharmaceutical companies to obtain savings on thousands of products and services.



Running the 340B UniversityTM, a HRSA-endorsed training program to assist stakeholders in remaining fully compliant with 340B rules and regulations.


Distribution Network

Providing a national network of traditional and specialty distributors to enable 340B-priced medications to reach participating hospitals and clinics.

Apexus Answers

Apexus Answers

Managing Apexus Answers, the national 340B call center, for all stakeholders.


Frequently Asked Questions (FAQs), or the most often asked inquires, are here for your convenience. Have a 340B question? It may have already been answered. View Apexus' FAQ page to find out.

340B Tools

Industry experts collaborated to create various tools and resources to assist entities in promoting 340B compliance and providing practical information about 340B program fundamentals.

Latest Events

Apexus keeps an up to date compilation of events relevant to 340B, including background information and registration links. This includes links to all 340B University sessions.

The Apexus Compass

OPA Staff Provides Update at ASHP Midyear Meeting

Michelle Herzog, Deputy Director of HRSA’s Office of Pharmacy Affairs provided an update during ASHP’s Midyear Clinical Meeting. A brief summary of her key points includes the following:

  • HRSA received 35 comments regarding the CMPs Notice of Proposed Regulation (NPRM) that was released in June, with the comment period closing in August. HRSA is currently evaluating the comments.

  • The Administrative Dispute Resolution NPRM is currently being drafted and is targeted to publish in 2016.

  • HRSA received 1,264 comments on the 340B omnibus guidelines published in August, with the comment period closing in October.

  • HRSA continues to enhance the Medicaid Exclusion File, which is the primary tool for preventing duplicate discounts through system fixes and continuing education. The areas of focus include fields of the file, quarterly changes, and provider identifiers. There is a dedicated email box for any comments, questions, concerns related to the exclusion file. It is OPAexclusion@hrsa.gov.

  • Since 2012, HRSA has conducted 444 on site audits encompassing over 5,000 outpatient facilities/sub-grantees and over 11,000 contract pharmacy locations. HRSA continues to rely on a risk stratification methodology, so that entities with higher risk factors are more likely to be selected for audit. Risk factors include: volume of purchases, # of child sites, # of contract pharmacies. HRSA has begun to remove child sites from hospitals for failure to be on the entity’s Medicare cost report and because the entity no longer owned and operated the child site. We have also removed contract pharmacies for lack of oversight by the covered entity.

  • HRSA conducted its first manufacturer audit in FY15 and the results have been posted on the OPA website. Additional manufacturer audits will be conducted by HRSA in FY 2016.

  • Per the statute, HRSA is required to collect information from manufacturers in order to verify the accuracy of 340B ceiling prices, and then make ceiling prices available to covered entities.

  • HRSA is currently working on the secure pricing system that will make ceiling prices available to covered entities via a secure process. This will also include spot checks of sales transactions. HRSA will be using analysis of these sales transactions as an early warning system to conduct proactive analysis and trending of pricing data to assess manufacturer compliance.

Scheduled Maintenance
February 5, 2016

ISMP January Newsletter
February 1, 2016

ISMP December Newsletter
December 28, 2015

ISMP November Newsletter
November 30, 2015

Taking the Chains Off 340B
November 5, 2015

ISMP October Newsletter
October 30, 2015

Orphan Drug Ruling
October 15, 2015

ISMP September Newsletter
September 30, 2015

ACCP and RI Award Grant
September 28, 2015

A New Place on the Continuum
September 23, 2015

ISMP August Newsletter
August 31, 2015

ISMP July Newsletter
July 30, 2015

ISMP June Newsletter
July 6, 2015

340B University San Diego
February 16, 2016

340B Coalition Winter Conference
February 17, 2016
Hotel Del Coronado, San Diego, CA

APhA 2016 Annual Meeting Exposition
March 4, 2016
Baltimore Convention Center, Baltimore, MD

ACHE Congress on Healthcare Leadership
March 14, 2016
Hyatt Regency Chicago, Chicago, IL

March 16, 2016
Marriott Wardman Park Hotel, Washington, DC